人表皮生长因子受体2阳性晚期乳腺癌
HER2-positive advanced breast cancer.
作者信息
Robert Nicholas J, Favret Anne M
机构信息
US Oncology Research Network, Fairfax Northern Virginia Hematology Oncology, 8503 Arlington Boulevard, #400, Fairfax, VA 22031, USA.
出版信息
Hematol Oncol Clin North Am. 2007 Apr;21(2):293-302. doi: 10.1016/j.hoc.2007.03.010.
It is important when treating a patient who has advanced breast cancer to establish the biologic characteristics of the tumor. In addition to knowing the hormone receptor status (estrogen and progesterone), human epidermal receptor 2 (HER2) should be evaluated. The measurement of this parameter is essential to optimizing the systemic management. This article reviews the biology of HER2, testing for HER2, clinical studies evaluating HER2-based therapies, side effects (specifically cardiotoxicity), and strategies for HER2-based therapies.
在治疗晚期乳腺癌患者时，确定肿瘤的生物学特征非常重要。除了解激素受体状态（雌激素和孕激素）外，还应评估人表皮受体2（HER2）。该参数的测量对于优化全身治疗至关重要。本文综述了HER2的生物学、HER2检测、评估基于HER2治疗的临床研究、副作用（特别是心脏毒性）以及基于HER2治疗的策略。
Zotero 插件